Latest market price
11.66
-0.81-6.50%
OverviewShort InterestFilings
NTLAQT30Intellia Therapeutics, Inc.·NASDAQ
11.66-6.50%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.07%$45.05NUVB-3.57%$4.59RARE+1.24%$16.30ABSI-12.94%$9.69QURE-7.49%$22.97URGN+5.01%$34.36MAZE-3.53%$30.37KLRA-5.52%$12.15
Snapshot
Index—P/E—EPS (ttm)-3.36Insider Own3.12%Shs Outstand140.13MPerf Week3.55%
Market Cap1.63BForward P/E—EPS next Y-2.63Insider Trans-0.92%Shs Float133.94MPerf Month-4.89%
Enterprise Value1.25BPEG—EPS next Q-0.80Short Float33.18%Perf Quarter3.00%
Income-400.00MP/S27.23EPS this Y—Short Ratio10.37Perf Half Y-15.93%
Sales60.00MP/B2.24EPS next Y—ROA-46.66%Short Interest44.44MPerf YTD29.70%
Book/sh5.20P/C3.73EPS next 5Y—ROE-57.79%52W High18.48 -36.90%Perf Year-4.97%
Cash/sh3.13P/FCF—EPS past 3/5Y—ROIC-52.86%52W Low7.95 46.67%Perf 3Y-53.36%
Dividend Est.—EV/EBITDA—Sales past 3/5Y9.35% 3.23%Gross Margin-46.48%Volatility9.18% 7.01%Perf 5Y-91.27%
Dividend TTM—EV/Sales20.76EPS Y/Y TTM—Oper. Margin-711.66%ATR (14)0.84Perf 10Y-15.38%
Dividend Ex-Date—Quick Ratio6.65Sales Y/Y TTM13.21%Profit Margin-672.16%RSI (14)46.36Recom2.33
Dividend Gr. 3/5Y—Current Ratio6.65EPS Q/Q19.19%SMA20-2.87%Beta1.79Target Price20.71
Payout0.00%Debt/Eq0.07Sales Q/Q-42.86%SMA50-4.50%Rel Volume0.88Prev Close12.47
Employees377LT Debt/Eq0.07EarningsNov 05SMA200-10.85%Avg Volume4.40MPrice11.66
IPO DateMay 06, 2016Option/ShortYes / YesEPS/Sales Surpr.-0.09% -40.99%Net Debt/EBITDA—Volume3,877,651Change-6.50%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-06-26InitiatedBarclaysUnderweight$24 → $8.00
Sep-09-26ReiteratedWedbushNeutral$17 → $13
Aug-07-26UpgradeEvercore ISI GroupIn Line → Outperform$8.00 → $24
Jul-16-26DowngradeWolfe ResearchPeer Perform → Underperform$9.00
Jul-10-26ReiteratedWedbushNeutral$9.00 → $17
Jun-15-26ReiteratedNew Street$25
May-13-26ReiteratedBernsteinMarket Perform$15 → $17
May-12-26ReiteratedCanaccord GenuityBuy
Apr-27-26ReiteratedLeerink PartnersOutperform$29 → $35
Apr-27-26ReiteratedRobert W. Baird$7.00 → $13
Latest News· Times ET
Oct-29-26
Oct-29-2604:35PM
Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesYahoo
08:00AM
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026globenewswire.com
Oct-28-26
Oct-28-2604:15PM
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Oct-21-26
Oct-21-2608:06AM
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsYahoo
04:15AM
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Surveydefenseworld.net
Oct-20-26
Oct-20-2611:30AM
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Nowzacks.com
Oct-18-26
Oct-18-2609:13AM
Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations AdvanceYahoo
Oct-13-26
Oct-13-2607:30AM
Intellia Therapeutics Appoints Jing L. Marantz, M.D.globenewswire.com
07:30AM
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical OfficerYahoo
Oct-12-26
Oct-12-2601:58AM
Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA)defenseworld.net
Oct-09-26
Oct-09-2608:56AM
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?zacks.com
Oct-08-26
Oct-08-2607:41AM
Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclaysdefenseworld.net
Oct-06-26
Oct-06-2604:09AM
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8Benzinga
Oct-02-26
Oct-02-2604:01PM
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Sep-29-26
Sep-29-2603:30AM
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha
Company

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue60685836—————
Cost of Goods Sold Incl. D&A8716109—————
Gross Profit-27524827—————
Selling, General and Administrative Excl. Other152120126116—————
Research and Development348389466435—————
Other Operating Expense-105-16-10-8—————
Operating Income-424-441-534-515—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)23281534—————
Net Income Before Taxes-400-413-519-481—————
Income Taxes
0000—————
Consolidated Net Income-400-413-519-481—————
Net Income From Continuing Operations-400-413-519-481—————
Net Income-400-413-519-481—————
EPS (Recurring)-3.36-3.81-5.25-5.42—————
EPS (Basic, Before Extraordinaries)-3.36-3.81-5.25-5.42—————
EPS (Diluted)-3.36-3.81-5.25-5.42—————
EBITDA-390-397-509-472—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio25.8514.2819.9075.38—————
Gross Margin-45.0076.4782.7675.00—————
Operating Margin-706.67-648.53-920.69-1,430.56—————
Net Margin-666.67-607.35-894.83-1,336.11—————
Shares Outstanding1331089989—————
Market Capitalization1,5519711,1542,714—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$30.97$24.49$18.01$11.53$5.05● Close Price0.00M0.35M0.70M1.05M1.40MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Dube Michael PVP, Chief Accounting OfficerOct 02 '26Sale12.431,86423,17065,022Oct 06
LEONARD JOHN MPresident and CEOAug 21 '26Sale13.002,78536,2051,147,064Aug 24
LEONARD JOHN MPresident and CEOAug 20 '26Sale12.6019,890250,6141,149,849Aug 24
Dulac Edward J IIIEVP, Chief Financial OfficerJul 22 '26Sale11.258,11191,249148,175Jul 24
Dulac Edward J IIIEVP, Chief Financial OfficerJul 02 '26Sale18.004,67784,186156,286Jul 06
Dube Michael PVP, Chief Accounting OfficerJul 01 '26Sale16.782,64144,31666,886Jul 06
BASTA JAMESEVP, General CounselMar 02 '26Sale13.781,21116,688156,794Mar 03
Clark ElianaEVP, Chief Technical OfficerMar 02 '26Sale13.786078,36493,864Mar 03
LEONARD JOHN MPresident and CEOJan 05 '26Sale9.2134,146314,4851,013,339Jan 07
Schultes Birgit CEVP, Chief Scientific OfficerJan 05 '26Sale9.218,50878,35998,533Jan 07
BASTA JAMESEVP, General CounselJan 05 '26Sale9.2110,39795,756101,528Jan 07
Cohen Fred EDirectorJan 05 '26Buy9.35150,0001,402,500207,453Jan 07
Lebwohl DavidEVP, Chief Medical OfficerJan 05 '26Sale9.2111,903109,627121,249Jan 07
Clark ElianaEVP, Chief Technical OfficerJan 05 '26Sale9.219,51587,63387,118Jan 07
Dulac Edward J IIIEVP, Chief Financial OfficerJan 05 '26Sale9.216,37958,75199,683Jan 07
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.